Cargando…

Whole-Genome DNA Methylation Profiling of CD14+ Monocytes Reveals Disease Status and Activity Differences in Crohn’s Disease Patients

Crohn’s disease (CD) is a multifactorial incurable chronic disorder. Current medical treatment seeks to induce and maintain a state of remission. During episodes of inflammation, monocytes infiltrate the inflamed mucosa whereupon they differentiate into macrophages with a pro-inflammatory phenotype....

Descripción completa

Detalles Bibliográficos
Autores principales:	Li Yim, Andrew Y.F., Duijvis, Nicolette W., Ghiboub, Mohammed, Sharp, Catriona, Ferrero, Enrico, Mannens, Marcel M.A.M., D’Haens, Geert R., de Jonge, Wouter J., te Velde, Anje A., Henneman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230341/ https://www.ncbi.nlm.nih.gov/pubmed/32276386 http://dx.doi.org/10.3390/jcm9041055

Ejemplares similares

A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn’s disease patients
por: Li Yim, Andrew Y. F., et al.
Publicado: (2018)

Peripheral blood methylation profiling of female Crohn’s disease patients
por: Li Yim, Andrew Y. F., et al.
Publicado: (2016)

Long-term Temporal Stability of Peripheral Blood DNA Methylation Profiles in Patients With Inflammatory Bowel Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Peripheral Blood DNA Methylation Profiles Do Not Predict Endoscopic Post-Operative Recurrence in Crohn’s Disease Patients
por: Joustra, Vincent W., et al.
Publicado: (2022)

Systematic Review and Meta-analysis of Peripheral Blood DNA Methylation Studies in Inflammatory Bowel Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
por: Marquès Camí, Miquel, et al.
Publicado: (2021)

The C-Type Lectin Mincle: Clues for a Role in Crohn’s Disease Adjuvant Reaction
por: te Velde, Anje A.
Publicado: (2017)

Nutritional Therapy Strategies in Pediatric Crohn’s Disease
por: Verburgt, Charlotte M., et al.
Publicado: (2021)

Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis
por: Duijvis, Nicolette W., et al.
Publicado: (2017)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Case report of cheilitis granulomatosa and joint complaints as presentation of Crohn’s disease
por: Hoekman, Daniël R., et al.
Publicado: (2016)

A prospective study comparing patient-reported outcomes in Crohn’s disease
por: Hoekman, Daniël R., et al.
Publicado: (2020)

Wound healing of metastatic perineal Crohn’s disease using hyperbaric oxygen therapy: A case series
por: Lansdorp, Corine A, et al.
Publicado: (2020)

Meta-Analysis of in vitro-Differentiated Macrophages Identifies Transcriptomic Signatures That Classify Disease Macrophages in vivo
por: Chen, Hung-Jen, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Assessing Disease Activity in Pediatric Crohn’s Disease Using Ultrasound: The Pediatric Crohn Disease Intestinal Ultrasound Score
por: van Wassenaer, Elsa A., et al.
Publicado: (2023)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease
por: Lansdorp, Corine A., et al.
Publicado: (2020)

Natural History and Risk Stratification of Recurrent Crohn’s Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study
por: Joustra, Vincent, et al.
Publicado: (2021)

Sustained Diet-Induced Remission in Pediatric Crohn’s Disease Is Associated With Kynurenine and Serotonin Pathways
por: Ghiboub, Mohammed, et al.
Publicado: (2023)

Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn’s Disease
por: Roblin, Xavier, et al.
Publicado: (2021)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFα Treatment in Crohn’s Disease
por: de Voogd, F, et al.
Publicado: (2022)

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
por: Elfiky, Ahmed M. I., et al.
Publicado: (2022)

Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease
por: Joustra, Vincent, et al.
Publicado: (2022)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
por: Strik, Anne S., et al.
Publicado: (2019)

Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
por: Feagan, Brian G., et al.
Publicado: (2022)

HDAC3 Mediates the Inflammatory Response and LPS Tolerance in Human Monocytes and Macrophages
por: Ghiboub, Mohammed, et al.
Publicado: (2020)

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease
por: de Bruyn, Jessica R., et al.
Publicado: (2018)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Hyperbaric oxygen therapy for the treatment of rectovaginal fistulas in patients with Crohn’s disease: results of the HOT-REVA pilot study
por: Lansdorp, C A, et al.
Publicado: (2021)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn’s Disease: Results from the EXTEND Trial
por: Reinisch, Walter, et al.
Publicado: (2017)

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study
por: Panés, Julián, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kgrevk1pn7487na51s9iikmuq3